vs
Fair Isaac（FICO）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是Fair Isaac的1.5倍（$772.1M vs $512.0M），Fair Isaac净利率更高（30.9% vs 12.7%，领先18.2%），Fair Isaac同比增速更快（16.4% vs 5.9%），Fair Isaac自由现金流更多（$173.9M vs $161.8M），过去两年Revvity的营收复合增速更高（9.0% vs 8.6%）
FICO（原Fair, Isaac and Company）是美国知名数据分析企业，1956年由比尔·费尔与厄尔·艾萨克创立，总部位于蒙大拿州博兹曼市，核心业务为信用评分服务，其推出的FICO信用分是评估消费者信贷风险的重要指标，目前已被美国消费信贷行业广泛采用。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
FICO vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.5倍
$512.0M
营收增速更快
FICO
高出10.5%
5.9%
净利率更高
FICO
高出18.2%
12.7%
自由现金流更多
FICO
多$12.1M
$161.8M
两年增速更快
RVTY
近两年复合增速
8.6%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $512.0M | $772.1M |
| 净利润 | $158.4M | $98.4M |
| 毛利率 | 83.0% | — |
| 营业利润率 | 45.7% | 14.5% |
| 净利率 | 30.9% | 12.7% |
| 营收同比 | 16.4% | 5.9% |
| 净利润同比 | 3.8% | 3.9% |
| 每股收益（稀释后） | $6.61 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FICORVTY
| Q4 25 | $512.0M | $772.1M | ||
| Q3 25 | $515.8M | $698.9M | ||
| Q2 25 | $536.4M | $720.3M | ||
| Q1 25 | $498.7M | $664.8M | ||
| Q4 24 | $440.0M | $729.4M | ||
| Q3 24 | $453.8M | $684.0M | ||
| Q2 24 | $447.8M | $691.7M | ||
| Q1 24 | $433.8M | $649.9M |
净利润FICORVTY
| Q4 25 | $158.4M | $98.4M | ||
| Q3 25 | $155.0M | $46.7M | ||
| Q2 25 | $181.8M | $53.9M | ||
| Q1 25 | $162.6M | $42.2M | ||
| Q4 24 | $152.5M | $94.6M | ||
| Q3 24 | $135.7M | $94.4M | ||
| Q2 24 | $126.3M | $55.4M | ||
| Q1 24 | $129.8M | $26.0M |
毛利率FICORVTY
| Q4 25 | 83.0% | — | ||
| Q3 25 | 82.3% | 53.6% | ||
| Q2 25 | 83.7% | 54.5% | ||
| Q1 25 | 82.4% | 56.5% | ||
| Q4 24 | 80.1% | — | ||
| Q3 24 | 80.3% | 56.3% | ||
| Q2 24 | 80.3% | 55.7% | ||
| Q1 24 | 80.0% | 54.6% |
营业利润率FICORVTY
| Q4 25 | 45.7% | 14.5% | ||
| Q3 25 | 46.0% | 11.7% | ||
| Q2 25 | 48.9% | 12.6% | ||
| Q1 25 | 49.3% | 10.9% | ||
| Q4 24 | 40.8% | 16.3% | ||
| Q3 24 | 43.4% | 14.3% | ||
| Q2 24 | 42.5% | 12.4% | ||
| Q1 24 | 44.9% | 6.8% |
净利率FICORVTY
| Q4 25 | 30.9% | 12.7% | ||
| Q3 25 | 30.1% | 6.7% | ||
| Q2 25 | 33.9% | 7.5% | ||
| Q1 25 | 32.6% | 6.4% | ||
| Q4 24 | 34.7% | 13.0% | ||
| Q3 24 | 29.9% | 13.8% | ||
| Q2 24 | 28.2% | 8.0% | ||
| Q1 24 | 29.9% | 4.0% |
每股收益（稀释后）FICORVTY
| Q4 25 | $6.61 | $0.86 | ||
| Q3 25 | $6.41 | $0.40 | ||
| Q2 25 | $7.40 | $0.46 | ||
| Q1 25 | $6.59 | $0.35 | ||
| Q4 24 | $6.14 | $0.77 | ||
| Q3 24 | $5.44 | $0.77 | ||
| Q2 24 | $5.05 | $0.45 | ||
| Q1 24 | $5.16 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $162.0M | $919.9M |
| 总债务越低越好 | $3.2B | — |
| 股东权益账面价值 | $-1.8B | $7.3B |
| 总资产 | $1.9B | $12.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资FICORVTY
| Q4 25 | $162.0M | $919.9M | ||
| Q3 25 | $134.1M | $931.4M | ||
| Q2 25 | $189.0M | $991.8M | ||
| Q1 25 | $146.6M | $1.1B | ||
| Q4 24 | $184.3M | $1.2B | ||
| Q3 24 | $150.7M | $1.2B | ||
| Q2 24 | $156.0M | $2.0B | ||
| Q1 24 | $135.7M | $1.7B |
总债务FICORVTY
| Q4 25 | $3.2B | — | ||
| Q3 25 | $3.1B | — | ||
| Q2 25 | $2.8B | — | ||
| Q1 25 | $2.5B | — | ||
| Q4 24 | $2.4B | — | ||
| Q3 24 | $2.2B | — | ||
| Q2 24 | $2.1B | — | ||
| Q1 24 | $2.0B | — |
股东权益FICORVTY
| Q4 25 | $-1.8B | $7.3B | ||
| Q3 25 | $-1.7B | $7.4B | ||
| Q2 25 | $-1.4B | $7.6B | ||
| Q1 25 | $-1.1B | $7.6B | ||
| Q4 24 | $-1.1B | $7.7B | ||
| Q3 24 | $-962.7M | $7.9B | ||
| Q2 24 | $-829.3M | $7.9B | ||
| Q1 24 | $-735.7M | $7.8B |
总资产FICORVTY
| Q4 25 | $1.9B | $12.2B | ||
| Q3 25 | $1.9B | $12.1B | ||
| Q2 25 | $1.9B | $12.4B | ||
| Q1 25 | $1.8B | $12.4B | ||
| Q4 24 | $1.7B | $12.4B | ||
| Q3 24 | $1.7B | $12.8B | ||
| Q2 24 | $1.7B | $13.4B | ||
| Q1 24 | $1.7B | $13.4B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $174.1M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $173.9M | $161.8M |
| 自由现金流率自由现金流/营收 | 34.0% | 21.0% |
| 资本支出强度资本支出/营收 | 0.0% | 2.6% |
| 现金转化率经营现金流/净利润 | 1.10× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $750.6M | $509.4M |
8季度趋势，按日历期对齐
经营现金流FICORVTY
| Q4 25 | $174.1M | $182.0M | ||
| Q3 25 | $223.7M | $138.5M | ||
| Q2 25 | $286.2M | $134.3M | ||
| Q1 25 | $74.9M | $128.2M | ||
| Q4 24 | $194.0M | $174.2M | ||
| Q3 24 | $226.5M | $147.9M | ||
| Q2 24 | $213.3M | $158.6M | ||
| Q1 24 | $71.0M | $147.6M |
自由现金流FICORVTY
| Q4 25 | $173.9M | $161.8M | ||
| Q3 25 | $219.5M | $120.0M | ||
| Q2 25 | $284.4M | $115.5M | ||
| Q1 25 | $72.8M | $112.2M | ||
| Q4 24 | $193.2M | $149.8M | ||
| Q3 24 | $224.7M | $125.6M | ||
| Q2 24 | $211.6M | $136.6M | ||
| Q1 24 | $67.0M | $129.7M |
自由现金流率FICORVTY
| Q4 25 | 34.0% | 21.0% | ||
| Q3 25 | 42.6% | 17.2% | ||
| Q2 25 | 53.0% | 16.0% | ||
| Q1 25 | 14.6% | 16.9% | ||
| Q4 24 | 43.9% | 20.5% | ||
| Q3 24 | 49.5% | 18.4% | ||
| Q2 24 | 47.2% | 19.7% | ||
| Q1 24 | 15.4% | 20.0% |
资本支出强度FICORVTY
| Q4 25 | 0.0% | 2.6% | ||
| Q3 25 | 0.8% | 2.6% | ||
| Q2 25 | 0.3% | 2.6% | ||
| Q1 25 | 0.4% | 2.4% | ||
| Q4 24 | 0.2% | 3.4% | ||
| Q3 24 | 0.4% | 3.3% | ||
| Q2 24 | 0.4% | 3.2% | ||
| Q1 24 | 0.9% | 2.7% |
现金转化率FICORVTY
| Q4 25 | 1.10× | 1.85× | ||
| Q3 25 | 1.44× | 2.97× | ||
| Q2 25 | 1.57× | 2.49× | ||
| Q1 25 | 0.46× | 3.03× | ||
| Q4 24 | 1.27× | 1.84× | ||
| Q3 24 | 1.67× | 1.57× | ||
| Q2 24 | 1.69× | 2.87× | ||
| Q1 24 | 0.55× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FICO
| Business To Business Scores | $248.6M | 49% |
| Saa S Products | $115.7M | 23% |
| Platform Software | $73.9M | 14% |
| Business To Consumer Scores | $55.9M | 11% |
| Technology Service | $19.2M | 4% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
